NCT00843037View on ClinicalTrials.gov

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
ParagangliomaPheochromocytoma
Interventions
DRUG

Sunitinib

50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)

Trial Locations (4)

T2N 4N2

Tom Baker Cancer Centre, Calgary

M5G 2M9

University Health Network, Princess Margaret Cancer Centre, Toronto

H2L 4M1

Hôpital Notre-Dame du CHUM, Montreal

Unknown

University Medical Centre Groningen, Groningen

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University Health Network, Toronto

OTHER